Highest-materiality recent filing
iRhythm to acquire Vital Connect for $287.5M in cash and stock
Total consideration $287.5M: $237.5M cash + $50M in iRhythm common stock.
iRhythm Q2 revenue $224M (+20% YoY), raises guidance; acquires VitalConnect for $287.5M
Revenue $224.2M (+20.1% YoY); net loss $0.4M vs $14.2M loss; adjusted EBITDA $43.3M (19.3% margin).
iRhythm discloses cyber incident with data exfiltration; threat actor demanded payment
Unauthorized activity identified June 8; threat actor demanded payment for not disclosing exfiltrated data including PHI and proprietary info.
iRhythm settles securities class action for $45M; expects insurance coverage for majority
Settlement payment of $45M to resolve putative class action securities lawsuit (Glazing Employers v. iRhythm Technologies).
iRhythm Q1 revenue $199.4M (+25.7%), net loss narrows; raises FY2026 outlook
Revenue of $199.4M, up 25.7% YoY; net loss $13.9M ($0.43/sh) vs $30.7M ($0.97/sh) in Q1 2025.
Q4 revenue $208.9M (+27.1% YoY); GAAP net income $5.6M ($0.17 diluted EPS), first positive quarterly net income in company history.
iRhythm Q3 beat: rev $192.9M up 31% YoY, net loss narrows to $5.2M; FY25 guidance raised
Revenue $192.9M, up 30.7% YoY; gross margin 71.1% (+230bps).
iRhythm Q2 revenue up 26.1% to $186.7M; net loss narrows to $14.2M; raises FY 2025 guidance
Revenue $186.7M (+26.1% YoY); gross margin 71.2% (+130 bps).
iRhythm Q1 revenue up 20% to $158.7M; raises FY 2025 guidance
Revenue $158.7M (+20.3% YoY); gross margin 68.8% (+250 bps).
iRhythm Q4 revenue up 24% to $164.3M; net loss narrows to $1.3M; guides FY2025 revenue $675-685M
Q4 revenue $164.3M (+24% YoY); gross margin 70.0% (+410bps). Net loss $1.3M vs $38.7M loss in Q4 2023.
iRhythm pre-announces FY2024 revenue above guidance; FY2025 outlook $675M-$685M
FY2024 revenue expected slightly above prior guidance of $587.5M (provided Oct 2024).
iRhythm Q3 revenue $147.5M (+18% YoY); gross margin 68.8% up 260 bps
Revenue $147.5M, up 18% YoY; gross profit $101.5M (+23%); gross margin 68.8% vs 66.2%
iRhythm licenses BioIntelliSense sensor tech for up to $35M + royalties; reaffirms FY2024 guidance
iRhythm pays $15M upfront and up to $20M in milestone payments for an exclusive ACM license of pulse oximetry, accelerometry, and non-invasive BP tech.
iRhythm Q2 revenue $148M (+19.3% YoY), raises FY24 guidance; names new CFO
Revenue of $148.0M, up 19.3% YoY; gross margin 69.9% (+40 bps YoY).
Revenue $131.9M (+18.4% YoY); gross margin 66.3% (down 160 bps YoY).
iRhythm closes $661.25M convertible note offering, repays $80.2M existing debt
Issued $661.25M aggregate principal of 1.50% Convertible Senior Notes due 2029, including full $86.25M greenshoe exercise.
iRhythm prices $575M convertible notes at 1.50%, upsized from $450M
$575M aggregate principal amount of 1.50% Convertible Senior Notes due 2029; upsized from $450M.
iRhythm proposes $450M convertible senior notes due 2029; repays $80.1M Braidwell loan
Offering $450M aggregate principal of 2029 convertible senior notes, plus $67.5M overallotment option.
iRhythm Q4 rev $132.5M (+17.7% YoY); net loss $38.7M; FY2024 guidance $575-585M
Revenue $132.5M in Q4 2023, up 17.7% YoY; full-year revenue $492.7M, up 19.9%.
iRhythm closes $150M Braidwell loan, Q4 registrations +22%, guides FY2024 rev ~$580M
Closed $150M Braidwell term loan (initial $75M funded, $75M delayed draw), interest margin 6.5-6.95%, matures Jan 2029, replaces SVB facility.
iRhythm Q3 2023 revenue $124.6M (+20% YoY); raises FY2023 guidance to $487.5M-$490M
Revenue $124.6M (+20% YoY); net loss $27.1M ($0.89/share) vs $21.5M loss in prior year.
iRhythm Q2 revenue $124.1M (+21.6% YoY); narrows net loss; guides FY rev $485-490M
Revenue $124.1M, up 21.6% YoY; gross margin 69.5%, up 70 bps from 68.8%.
FDA warning letter to iRhythm for Zio AT System quality and reporting violations
FDA alleges non-conformities in medical device reporting and quality system requirements for Zio AT System.
iRhythm reports Q1 revenue $111.4M (+20.6% YoY); updates FY2023 guidance to $480-$490M
Revenue $111.4M (+20.6% YoY); gross margin 67.9%, up 100 bps from 66.9%.
iRhythm updates cash position: $54.5M at SVB; affirms sufficient liquidity outside SVB
Held $54.5M in operating accounts at Silicon Valley Bank and $24.4M in money market funds outside SVB as of Dec 31, 2022.
iRhythm Q4 revenue $112.6M (+37.7% YoY); adjusted EBITDA positive $1.1M; guides 2023 rev $475-485M
Q4 revenue $112.6M (+37.7% YoY); gross margin 69.9% (up 720 bps); net loss $20.2M ($0.67 loss per share) vs $32.5M loss in Q4 2021.
iRhythm Q3 revenue $103.9M (+21.6% YoY); cuts FY22 revenue guidance to $407-411M
Revenue $103.9M (+21.6% YoY); net loss $21.5M ($0.71/sh) vs $23.7M loss in Q3 2021.
iRhythm sets $1B revenue target by 2027, reaffirms FY2022 guidance, targets 15% EBITDA margin
Reaffirms FY2022 guidance: revenue $415-420M (29-30% growth), gross margin 68-69%, adjusted EBITDA loss $12.5-17.5M.
iRhythm Q2 revenue $102.1M (+26% YoY), raises FY22 guidance to $415-420M, loss widens
Revenue $102.1M (+25.6% YoY); gross margin 68.8% (up 0.8pp).
iRhythm CCO David Vort resigns; Chad Patterson appointed; Q2 volumes slightly ahead of guidance
David Vort resigns as CCO effective July 25, 2022, will serve as strategic advisor through March 2023.
On January 23, 2025, Mojdeh Poul notified iRhythm Technologies, Inc. (the “Company”) of her decision to not seek re-election to the Board of Directors of the Company (the “Board”) at the expiration of her current term, which term ends on the date of the Company’s next annual meeting of stockholders.
On July 31, 2024, the Board of Directors (the “Board”) of the Company appointed Daniel Wilson as the Company’s Chief Financial Officer and principal financial officer, effective as of August 31, 2024.
On August 1, 2024, iRhythm Technologies, Inc. (the “Company”) announced that Brice Bobzien resigned from his position as Chief Financial Officer of the Company, and his employment with the Company, effective August 31, 2024 (the “Separation Date”).
On August 11, 2023, the board of directors (the “Board”) of iRhythm Technologies, Inc. (the “Company”) appointed Marc Rosenbaum, the Company’s Senior Vice President, Finance, to serve as the Company’s Chief Accounting Officer
Effective as of June 1, 2023, the Board of Directors (the “Board”) of iRhythm Technologies, Inc. (the “Company”) elected each of Mojdeh Poul and Brian Yoor as a director of the Board and member of the Audit Committee of the Board.
Effective as of June 1, 2023, the Board of Directors (the “Board”) of iRhythm Technologies, Inc. (the “Company”) elected each of Mojdeh Poul and Brian Yoor as a director of the Board and member of the Audit Committee of the Board.
Daniel Wilson’s role will change from the Company’s Executive Vice President of Corporate Strategy, Corporate Development and Investor Relations to Executive Vice President of Corporate Development and Investor Relations
Douglas Devine resigned from his position as Chief Operating Officer of the Company
Brice Bobzien had been appointed as the Company’s Chief Financial Officer
Reyna Fernandez had been appointed as the Company’s EVP, Chief Human Resources Officer
Douglas Devine has agreed to resign from his position as Chief Financial Officer of the Company on Mr. Bobzien’s first day of employment
On July 18, 2022, David A. Vort resigned from his position as Executive Vice President, Chief Commercial Officer of the Company, effective as of July 25, 2022.
Max materiality 0.85 · Median 0.68 · Most common event earnings